Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Cardiovascular effects of nicotine

Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA
Section Editor
Neal L Benowitz, MD
Deputy Editors
Judith A Melin, MA, MD, FACP
Gordon M Saperia, MD, FACC


Nicotine is a naturally occurring alkaloid found primarily in tobacco. It is most commonly absorbed from cigarette smoke. A cigarette contains 10 to 15 mg nicotine and delivers on average 1 mg nicotine to the smoker. Nicotine is also available from smokeless tobacco (snuff, chewing tobacco), pipe and cigar tobacco, waterpipe tobacco, electronic cigarettes (e-cigarettes), and a variety of smoking cessation medications. Nicotine is also present in some insecticides, which may be a source of accidental or intentional poisoning.


The peak plasma nicotine concentration during smoking is 10 to 50 ng/mL with about 5 percent being protein-bound. The half-life averages two hours. Approximately 80 to 90 percent of nicotine is metabolized by lung, liver, and kidney; the principal metabolite is cotinine, which has a plasma concentration that is 10-fold higher than nicotine. Cotinine has a half-life of 15 to 20 hours and is used as a biomarker of nicotine exposure [1].

Approximately 17 percent of nicotine is excreted unchanged in the urine. The rate of urinary excretion is pH-dependent, decreasing in an alkaline urine. Nicotine is found in the milk of lactating women with concentrations that parallel those of plasma.

Racial differences in tobacco-related diseases are not fully explained by cigarette-smoking behavior. Despite smoking fewer cigarettes per day, black smokers have higher levels of serum cotinine. A study comparing the daily intake and rate of metabolism of nicotine in black smokers and white smokers found that the tobacco smoke and nicotine intake per cigarette was 30 percent higher in black smokers, while total and nonrenal clearances of cotinine were significantly lower (by 10 to 15 percent) in black smokers [2]. Thus, both a higher nicotine intake and slower rate of cotinine metabolism account for the higher serum cotinine concentrations in black smokers.


Cytochrome P450 2A6 gene — Interindividual variability in the plasma concentrations of nicotine and cotinine is considerable during smoking, even among individuals taking in similar doses of nicotine. Nicotine is metabolized primarily by the liver enzyme cytochrome P450 2A6 (CYP2A6). A number of CYP2A6 gene variants have been described, several of which are associated with slower metabolism of nicotine. Some individuals have been described with CYP2A6 gene deletions who metabolize nicotine unusually slowly and generate little cotinine. Gene variants associated with slow metabolism are more prevalent among Asians and blacks. Genetically slow metabolizers tend to smoke fewer cigarettes per day and are able to quit smoking more easily than fast metabolizers [3].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Jul 27, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57:79.
  2. Pérez-Stable EJ, Herrera B, Jacob P 3rd, Benowitz NL. Nicotine metabolism and intake in black and white smokers. JAMA 1998; 280:152.
  3. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77:145.
  4. Stevens VL, Bierut LJ, Talbot JT, et al. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev 2008; 17:3517.
  5. Saccone NL, Saccone SF, Hinrichs AL, et al. Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:453.
  6. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36:597.
  7. Benowitz NL, Kuyt F, Jacob P 3rd. Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. Clin Pharmacol Ther 1984; 36:74.
  8. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295:573.
  9. Narkiewicz K, van de Borne PJ, Hausberg M, et al. Cigarette smoking increases sympathetic outflow in humans. Circulation 1998; 98:528.
  10. Okamura T, Toda N. Mechanism underlying nicotine-induced relaxation in dog saphenous arteries. Eur J Pharmacol 1994; 263:85.
  11. Kannel WB. Hypertension, blood lipids, and cigarette smoking as co-risk factors for coronary heart disease. Ann N Y Acad Sci 1978; 304:128.
  12. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115:242.
  13. McBride PE. The health consequences of smoking. Cardiovascular diseases. Med Clin North Am 1992; 76:333.
  14. Freestone S, Ramsay LE. Effect of coffee and cigarette smoking on the blood pressure of untreated and diuretic-treated hypertensive patients. Am J Med 1982; 73:348.
  15. Pickering TG, Schwartz JE, James GD. Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Clin Exp Pharmacol Physiol 1995; 22:226.
  16. Kool MJ, Hoeks AP, Struijker Boudier HA, et al. Short- and long-term effects of smoking on arterial wall properties in habitual smokers. J Am Coll Cardiol 1993; 22:1881.
  17. Mikkelsen KL, Wiinberg N, Høegholm A, et al. Smoking related to 24-h ambulatory blood pressure and heart rate: a study in 352 normotensive Danish subjects. Am J Hypertens 1997; 10:483.
  18. Green MS, Jucha E, Luz Y. Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J 1986; 111:932.
  19. Perkins KA, Epstein LH, Marks BL, et al. The effect of nicotine on energy expenditure during light physical activity. N Engl J Med 1989; 320:898.
  20. Benowitz NL, Sharp DS. Inverse relation between serum cotinine concentration and blood pressure in cigarette smokers. Circulation 1989; 80:1309.
  21. Klein LW, Ambrose J, Pichard A, et al. Acute coronary hemodynamic response to cigarette smoking in patients with coronary artery disease. J Am Coll Cardiol 1984; 3:879.
  22. Nicod P, Rehr R, Winniford MD, et al. Acute systemic and coronary hemodynamic and serologic responses to cigarette smoking in long-term smokers with atherosclerotic coronary artery disease. J Am Coll Cardiol 1984; 4:964.
  23. Quillen JE, Rossen JD, Oskarsson HJ, et al. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J Am Coll Cardiol 1993; 22:642.
  24. Winniford MD, Wheelan KR, Kremers MS, et al. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation 1986; 73:662.
  25. Caralis DG, Deligonul U, Kern MJ, Cohen JD. Smoking is a risk factor for coronary spasm in young women. Circulation 1992; 85:905.
  26. Iida M, Iida H, Dohi S, et al. Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo. Stroke 1998; 29:1656.
  27. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113:1006.
  28. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; 2:986.
  29. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76:6.
  30. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 1993; 22:1159.
  31. Benowitz NL. The role of nicotine in smoking-related cardiovascular disease. Prev Med 1997; 26:412.
  32. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92:2432.
  33. Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26:1222.
  34. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336:1276.
  35. Zidovetzki R, Chen P, Fisher M, et al. Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway. Stroke 1999; 30:651.
  36. Barbash GI, White HD, Modan M, et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation 1993; 87:53.
  37. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992; 85:1254.
  38. Grines CL, Topol EJ, O'Neill WW, et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 1995; 91:298.
  39. Gomez MA, Karagounis LA, Allen A, Anderson JL. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. TEAM-2 Investigators. Second Multicenter Thrombolytic Trials of Eminase in Acute Myocardial Infarction. Am J Cardiol 1993; 72:373.
  40. Rivers JT, White HD, Cross DB, et al. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. J Am Coll Cardiol 1990; 16:340.
  41. Galan KM, Deligonul U, Kern MJ, et al. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 61:260.
  42. Mjøs OD. Lipid effects of smoking. Am Heart J 1988; 115:272.
  43. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation 1992; 86:839.
  44. Freeman DJ, Griffin BA, Murray E, et al. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest 1993; 23:630.
  45. Harats D, Ben-Naim M, Dabach Y, et al. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis 1989; 79:245.
  46. Nilsson P, Lundgren H, Söderström M, et al. Effects of smoking cessation on insulin and cardiovascular risk factors--a controlled study of 4 months' duration. J Intern Med 1996; 240:189.
  47. Terres W, Becker P, Rosenberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994; 97:242.
  48. Criqui MH, Cowan LD, Tyroler HA, et al. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results form the Lipid Research Clinics Follow-up Study. Am J Epidemiol 1987; 126:629.
  49. Sun YP, Zhu BQ, Browne AE, et al. Nicotine does not influence arterial lipid deposits in rabbits exposed to second-hand smoke. Circulation 2001; 104:810.
  50. Neunteufl T, Heher S, Kostner K, et al. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J Am Coll Cardiol 2002; 39:251.
  51. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88:2149.
  52. Campisi R, Czernin J, Schöder H, et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 1998; 98:119.
  53. Nitenberg A, Antony I, Foult JM. Acetylcholine-induced coronary vasoconstriction in young, heavy smokers with normal coronary arteriographic findings. Am J Med 1993; 95:71.
  54. Kiowski W, Linder L, Stoschitzky K, et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994; 90:27.
  55. Howard G, Burke GL, Szklo M, et al. Active and passive smoking are associated with increased carotid wall thickness. The Atherosclerosis Risk in Communities Study. Arch Intern Med 1994; 154:1277.
  56. Baldassarre D, Castelnuovo S, Frigerio B, et al. Effects of timing and extent of smoking, type of cigarettes, and concomitant risk factors on the association between smoking and subclinical atherosclerosis. Stroke 2009; 40:1991.
  57. Christen AG, Swanson BZ, Glover ED, Henderson AH. Smokeless tobacco: the folklore and social history of snuffing, sneezing, dipping, and chewing. J Am Dent Assoc 1982; 105:821.
  58. World Health Organization. Tobacco: Deadly in any form or disguise. World Health Organization, Geneva, Switzerland, 2006.
  59. World Health Organization. WHO Report on the Global Tobacco Epidemic. World Health Organization, Geneva, Switzerland, 2008.
  60. Delnevo CD, Giovenco DP, Steinberg MB, et al. Patterns of Electronic Cigarette Use Among Adults in the United States. Nicotine Tob Res 2016; 18:715.
  61. Smokeless Tobacco Fact Sheets. 3rd International Conference on Smokeless Tobacco, September 20-25. National Cancer Institute, 2002.
  62. Hatsukami DK, Joseph AM, Lesage M, et al. Developing the science base for reducing tobacco harm. Nicotine Tob Res 2007; 9 Suppl 4:S537.
  63. Djordjevic MV, Doran KA. Nicotine content and delivery across tobacco products. Handb Exp Pharmacol 2009; :61.
  64. Siegel D, Benowitz N, Ernster VL, et al. Smokeless tobacco, cardiovascular risk factors, and nicotine and cotinine levels in professional baseball players. Am J Public Health 1992; 82:417.
  65. Eliasson M, Asplund K, Nasic S, Rodu B. Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study. J Intern Med 2004; 256:101.
  66. Hergens MP, Ahlbom A, Andersson T, Pershagen G. Swedish moist snuff and myocardial infarction among men. Epidemiology 2005; 16:12.
  67. Hergens MP, Lambe M, Pershagen G, Ye W. Risk of hypertension amongst Swedish male snuff users: a prospective study. J Intern Med 2008; 264:187.
  68. Benowitz NL. Sodium intake from smokeless tobacco. N Engl J Med 1988; 319:873.
  69. Benowitz NL, Porchet H, Sheiner L, Jacob P 3rd. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44:23.
  70. Benowitz NL. Nicotine and smokeless tobacco. CA Cancer J Clin 1988; 38:244.
  71. Piano MR, Benowitz NL, Fitzgerald GA, et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation 2010; 122:1520.
  72. Accortt NA, Waterbor JW, Beall C, Howard G. Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol 2002; 156:730.
  73. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005; 16:347.
  74. Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies. Eur J Cardiovasc Prev Rehabil 2004; 11:101.
  75. Lee PN. Circulatory disease and smokeless tobacco in Western populations: a review of the evidence. Int J Epidemiol 2007; 36:789.
  76. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009; 339:b3060.
  77. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368:647.
  78. Hergens MP, Lambe M, Pershagen G, et al. Smokeless tobacco and the risk of stroke. Epidemiology 2008; 19:794.
  79. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013; 382:1629.
  80. Moheimani RS, Bhetraratana M, Yin F, et al. Increased Cardiac Sympathetic Activity and Oxidative Stress in Habitual Electronic Cigarette Users: Implications for Cardiovascular Risk. JAMA Cardiol 2017; 2:278.
  81. Institute of Medicine. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence, The National Academies Press, . Washington, DC 2010.
  82. Heiss C, Amabile N, Lee AC, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol 2008; 51:1760.
  83. Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298:2654.
  84. Eliasson B, Taskinen MR, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation 1996; 94:878.
  85. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29:1422.
  86. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest 1996; 109:438.
  87. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792.
  88. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch Intern Med 1994; 154:989.
  89. Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37:1297.
  90. Woolf KJ, Zabad MN, Post JM, et al. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012; 110:968.
  91. Hurt RD, Weston SA, Ebbert JO, et al. Myocardial infarction and sudden cardiac death in Olmsted County, Minnesota, before and after smoke-free workplace laws. Arch Intern Med 2012; 172:1635.
  92. Ockene JK, Hosmer D, Rippe J, et al. Factors affecting cigarette smoking status in patients with ischemic heart disease. J Chronic Dis 1985; 38:985.